Telix Pharmaceuticals Ltd (ASX:TLX) is a commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer, which pair a precision diagnostic with a targeted therapy. Its commercial portfolio includes Illuccix, a prostate cancer imaging agent available in 22 countries, Gozellix, approved by the FDA for prostate imaging, and Pixclara, approved for glioma imaging. Telix also has three late-stage therapeutic candidates in pivotal trials. The company is headquartered in Melbourne and is listed on the ASX and Nasdaq.

On 2 October 2026, Telix shares were trading at $15.16, down 2.88%. The company's most recent announcement concerned a regulatory designation for one of its diagnostic development programs.

Telix operates across North America, Europe, Latin America and Asia-Pacific. Its approach centres on theranostics, using the same molecular target for both imaging and therapy, which allows clinicians to identify patients who may benefit from targeted radiation treatment.

Recent Developments

On 30 September 2026, Telix announced that the US FDA had granted Fast Track Designation for its BiPASS program. Key details include:

  • BiPASS (Biopsy of the Prostate Avoidance Stratification Study) is evaluating gallium-68 PSMA-PET imaging alongside MRI for detecting prostate cancer before biopsy.
  • Fast Track is designed to facilitate development and expedite review of drugs for serious conditions with unmet medical need, and allows more frequent engagement with the FDA.
  • Telix recently completed enrolment in the Phase 3 BiPASS study of its Illuccix and Gozellix agents.
  • The company has engaged with the FDA on a New Drug Application (NDA) pathway and is planning its submission.

Telix noted that more than three million prostate biopsies are performed globally each year, yet up to 75% produce a negative result, and biopsy can be stressful and painful for patients. BiPASS builds on the PRIMARY and PRIMARY2 studies, which showed that combining gallium-68 PSMA-PET with MRI can improve detection of clinically significant prostate cancer while reducing unnecessary biopsies by almost 50%. The company said BiPASS is not intended to replace biopsy where it benefits the patient, but to help clinicians decide which patients need biopsy and where it should be targeted.

Group Chief Medical Officer Dr David N. Cade said the designation reflects the FDA's recognition of the potential for BiPASS to address an important unmet need. The NDA pathway would support registration as a new product, broadening access to gallium-68 PSMA-PET imaging for a larger patient population if approved. The use of Illuccix and Gozellix in the pre-biopsy setting remains investigational. Telix's therapeutic pipeline includes TLX591-Tx in prostate cancer, TLX101-Tx in recurrent glioblastoma and TLX250-Tx in kidney cancer.

Illuccix and Gozellix are currently approved for PET imaging of PSMA-positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, or who have suspected recurrence based on elevated PSA levels. Illuccix is also approved for selecting patients for PSMA-directed therapy. The BiPASS program aims to move PSMA-PET imaging earlier, before a biopsy decision is made. The announcement was authorised for release by Telix's Disclosure Committee on behalf of the board. Telix said Fast Track facilitates more frequent engagement with the FDA and may enable expedited review of the planned NDA, which could accelerate patient access if approved.

Sector Context

Radiopharmaceuticals have become a growing area of oncology, combining diagnostic imaging and targeted radiation therapy. PSMA-PET imaging has transformed prostate cancer staging, and companies are seeking to expand its use earlier in the diagnostic pathway. Several large pharmaceutical companies have invested in radiopharmaceuticals through acquisitions and partnerships.

The sector faces challenges including isotope supply, Manufacturing logistics and regulatory requirements. Reimbursement and adoption depend on demonstrating clinical value. Competition in PSMA imaging includes other approved agents.

Prostate cancer is one of the most commonly diagnosed cancers in men, and diagnostic pathways typically involve PSA testing, MRI and biopsy. Reducing unnecessary biopsies is a goal for many health systems, as procedures carry risks and costs. Imaging agents that improve the accuracy of pre-biopsy assessment could change clinical practice if supported by trial data and guidelines. Gallium-68 based agents require generators or cyclotron-produced isotopes and established distribution networks.

Risks and Uncertainties

Fast Track designation does not guarantee approval, and the BiPASS NDA must demonstrate sufficient evidence for the pre-biopsy indication. Telix's therapeutic candidates are still in trials and have not received Marketing authorisation. Competition in PSMA-PET imaging could affect market share. Isotope Supply constraints and manufacturing issues could affect sales. Telix has noted risks including tariffs, geopolitical conflict and pricing and reimbursement uncertainties.

The company's forward-looking statements highlight uncertainties around trial timing, regulatory filings, manufacturing, raw material supply and the effect of US and foreign tariffs. Market acceptance of an imaging-first approach to prostate cancer diagnosis will depend on clinician adoption and reimbursement.

The company's operations across multiple regions also expose it to currency movements and differing regulatory requirements.

Catalysts Investors Can Watch

Investors may watch for the BiPASS NDA submission, Phase 3 BiPASS data, progress on TLX591-Tx, TLX101-Tx and TLX250-Tx, and sales trends for Illuccix and Gozellix. Further regulatory designations or approvals may also be relevant.

Investors may also follow any updates on Pixclara's commercial launch for glioma imaging and expansion of Illuccix into additional countries. Data from the therapeutic programs could be significant catalysts given their pivotal-stage status.

Final Thoughts

Telix's FDA Fast Track designation for BiPASS supports its plan to expand PSMA-PET imaging into pre-biopsy diagnosis. The NDA submission and therapeutic pipeline progress are likely to be key areas to follow.

Its commercial imaging Franchise provides Revenue as it advances its therapeutic pipeline.